Emerald Mutual Fund Advisers Trust Makes New Investment in Savara Inc (NASDAQ:SVRA)

Emerald Mutual Fund Advisers Trust purchased a new position in shares of Savara Inc (NASDAQ:SVRA) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,375,888 shares of the company’s stock, valued at approximately $4,224,000. Emerald Mutual Fund Advisers Trust owned approximately 0.80% of Savara at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Savara by 4.6% in the 4th quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company’s stock worth $25,512,000 after purchasing an additional 365,959 shares in the last quarter. Nantahala Capital Management LLC raised its holdings in shares of Savara by 45.2% in the 4th quarter. Nantahala Capital Management LLC now owns 7,525,259 shares of the company’s stock worth $23,103,000 after purchasing an additional 2,344,308 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Savara by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 2,784,037 shares of the company’s stock worth $8,549,000 after purchasing an additional 57,187 shares in the last quarter. Rosalind Advisors Inc. bought a new stake in shares of Savara in the 4th quarter worth approximately $8,151,000. Finally, Emerald Advisers LLC bought a new stake in shares of Savara in the 4th quarter worth approximately $7,161,000. 87.93% of the stock is currently owned by institutional investors.

Savara Price Performance

Savara stock opened at $3.19 on Tuesday. The business’s 50-day simple moving average is $2.78 and its 200 day simple moving average is $3.06. The stock has a market cap of $550.70 million, a price-to-earnings ratio of -7.42 and a beta of 0.52. Savara Inc has a 12-month low of $2.26 and a 12-month high of $5.31. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The company had revenue of $0.27 million during the quarter. As a group, research analysts anticipate that Savara Inc will post -0.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Savara in a report on Friday, March 28th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Savara has a consensus rating of “Moderate Buy” and a consensus price target of $8.83.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.